Impaired counter-regulation of interleukin-1 by the soluble IL-1 receptor type II in patients with chronic liver disease

References

• Diehl AM. Cytokine regulation of liver injury and repair. Immunol Rev 2000; 174: 160–71
   PubMed Web of Science ®Google Scholar
• Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103: 264–74
   PubMed Web of Science ®Google Scholar
• Tsutsui H, Matsui K, Okamura H, Nakanishi K. Pathophysiological roles of interleukin-18 in inflammatory liver diseases. Immunol Rev 2000; 174: 192–209
   PubMed Web of Science ®Google Scholar
• Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343: 1467–76
   PubMed Web of Science ®Google Scholar
• Bird GL, Sheron N, Goka AK, Alexander GJ, Williams RS. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990; 112: 917–20
   PubMed Web of Science ®Google Scholar
• Felver ME, Mezey E, McGuire M, Mitchell MC, Herlong HF, Veech GA, et al. Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res 1990; 14: 255–9
   PubMed Web of Science ®Google Scholar
• McClain CJ, Cohen DA, Dinarello CA, Cannon JG, Shedlofsky SI, Kaplan AM. Serum interleukin-1 (IL-1) activity in alcoholic hepatitis. Life Sci 1986; 39: 1479–85
   PubMed Web of Science ®Google Scholar
• Hill DB, Marsano L, Cohen D, Allen J, Shedlofsky S, McClain CJ. Increased plasma interleukin-6 concentrations in alcoholic hepatitis. J Lab Clin Med 1992; 119: 547–52
   PubMed Web of Science ®Google Scholar
• Sheron N, Bird G, Koskinas J, Portmann B, Ceska M, Lindley I, et al. Circulating and tissue levels of the neutrophil chemotaxin interleukin-8 are elevated in severe acute alcoholic hepatitis, and tissue levels correlate with neutrophil infiltration. Hepatology 1993; 18: 41–6
   PubMed Web of Science ®Google Scholar
• Hassan G, Moreno S, Massimi M, Di Biagio P, Stefanini S. Interleukin-1-producing plasma cells in close contact with hepatocytes in patients with chronic active hepatitis. J Hepatol 1997; 27: 6–17
   PubMed Web of Science ®Google Scholar
• Dinarello CA. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000; 343: 732–4
   PubMed Web of Science ®Google Scholar
• Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993; 54: 167–227
   PubMed Web of Science ®Google Scholar
• Symons JA, Duff GW. A soluble form of the interleukin-1 receptor produced by a human B cell line. FEBS Lett 1990; 272: 133–6
   PubMed Web of Science ®Google Scholar
• Symons JA, Eastgate JA, Duff GW. Purification and characterization of a novel soluble receptor for interleukin 1. J Exp Med 1991; 174: 1251–4
   PubMed Web of Science ®Google Scholar
• Casini-Raggi V, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995; 154: 2434–40
   PubMed Web of Science ®Google Scholar
• Youngman KR, Simon PL, West GA, Cominelli F, Rachmilewitz D, Klein JS, et al. Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology 1993; 104: 749–58
   PubMed Web of Science ®Google Scholar
• Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343: 336–40
   PubMed Web of Science ®Google Scholar
• Dripps DJ, Brandhube BJ, Thompson RC, Eisenberg SP. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 1991; 266: 10331–6
   PubMed Web of Science ®Google Scholar
• Ferretti M, Casini-Raggi V, Pizarro TT, Eisenberg SP, Nast CC, Cominelli F. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 1994; 94: 449–53
   PubMed Web of Science ®Google Scholar
• Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest 1997; 99: 2930–40
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993; 328: 106–13
   PubMed Web of Science ®Google Scholar
• Giri JG, Newton RC, Horuk R. Identification of soluble interleukin-1 binding protein in cell-free supernatants. Evidence for soluble interleukin-1 receptor. J Biol Chem 1990; 265: 17416–9
   PubMed Web of Science ®Google Scholar
• Arend WP, Malyak M, Smith MF, Jr, Whisenand TD, Slack JL, Sims JE, et al. Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol 1994; 153: 4766–74
   PubMed Web of Science ®Google Scholar
• Symons JA, Young PR, Duff GW. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci USA 1995; 92: 1714–8
   PubMed Web of Science ®Google Scholar
• Mullberg J, Rauch CT, Wolfson MF, Castner B, Fitzner JN, Otten-Evans C, et al. Further evidence for a common mechanism for shedding of cell surface proteins. FEBS Lett 1997; 401: 235–8
   PubMed Web of Science ®Google Scholar
• Buger D, Chicheportiche R, Giri JG, Dayer JM. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest 1995; 96: 38–41
   PubMed Web of Science ®Google Scholar
• Giri JG, Wells J, Dower SK, McCall CE, Guzman RN, Slack, et al. Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. J Immunol 1994; 153: 5802–9
   PubMed Web of Science ®Google Scholar
• Preas HL, Reda D, Tropea M, Vandivier RW, Banks SM, Agosti JM, et al. Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. Blood 1996; 88: 2465–72
   PubMed Web of Science ®Google Scholar
• Gabay C, Genin B, Mentha G, Iynedjian PB, Roux-Lombard P, Guerne PA. IL-1 receptor antagonist (IL-1Ra) does not inhibit the production of C-reactive protein or serum amyloid A protein by human primary hepatocytes. Differential regulation in normal and tumour cells. Clin Exp Immunol 1995; 100: 306–13
   PubMed Web of Science ®Google Scholar
• Gabay C, Silacci P, Genin B, Mentha G, Le Coultre C, Guerne PA. Soluble interleukin-6 receptor strongly increases the production of acute-phase protein by hepatoma cells but exerts minimal changes on human primary hepatocytes. Eur J Immunol 1995; 25: 2378–83
   PubMed Web of Science ®Google Scholar
• Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol 1976; 13: 29–83
   PubMedGoogle Scholar
• Jouvenne P, Vannier E, Dinarello CA, Miossec P. Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. Arthritis Rheum 1998; 41: 1083–9
   PubMed Web of Science ®Google Scholar
• Ludwiczek O, Vannier E, Borggraefe I, Kaser A, Siegmund B, Dinarello CA, et al. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol 2004; 138: 323–9
   PubMed Web of Science ®Google Scholar
• Poutsiaka DD, Clark BD, Vannier E, Dinarello CA. Production of interleukin-1 receptor antagonist and interleukin-1 beta by peripheral blood mononuclear cells is differentially regulated. Blood 1991; 78: 1275–81
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095–147
   PubMed Web of Science ®Google Scholar
• Smith RJ, Chin JE, Sam LM, Justen JM. Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum 1991; 34: 78–83
   PubMed Web of Science ®Google Scholar